Abstract
Purpose
Adjusted indirect comparisons can be used to investigate bioequivalence between generic products that are bioequivalent with a common reference product. In previous work with generic tuberculosis medicines prequalified by the WHO, it was observed that although indirect comparisons are an effective approach for confirming the interchangeability of generics, the approach is subject to less precision than direct comparisons. The objective of this investigation was to explore this by examining the influence of point estimates and power of bioequivalence studies versus the reference on the ability to show equivalence in indirect comparisons.
Methods
Power was considered as a determining factor instead of variability and sample size, because sample size is calculated based on variability and desired power. Scenarios were computed combining a range of point estimate differences (0–14 %) and statistical power of the studies (50–99.99 %).
Results
The indirect comparisons could conclude equivalence between generics only when (a) point estimate differences between generics were low (≤5.5 %) for any sufficiently powered study (>80 %), or (b) the differences were large (but less than 14 %) and both bioequivalence studies were overpowered (e.g., 10 % difference and power ≥95 %).
Conclusions
In summary, the ability to demonstrate interchangeability between generics is dependent not only on the real differences between the products but also on the design of the original generic vs. reference bioequivalence studies being combined, as earmarked by their respective power.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
World Health Organization (2006) Annex 7: multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: WHO technical report series 937: WHO expert committee on specifications for pharmaceutical preparations. WHO Press, Geneva, pp. 347–390
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2003) Bioavailability and bioequivalence. Studies for orally administered drug products-general considerations. CDER, Washington D.C.
Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the investigation of bioequivalence. European Medicines Agency (EMA), London
Chow, S.C., Liu, J.P., (2000) Design and analysis of bioavailability and bioequivalence studies. 2nd ed. New York: Marcel Dekker.
Gwaza L, Gordon J, Welink J, Potthast H, Hansson H, Stahl M, et al (2012) (2012) Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. Eur J Clin Pharmacol 68:1611–1618
‘t Hoen EF, Hogerzeil HV, Quick JD, Sillo HB (2014) A quiet revolution in global public health: the World Health Organization's prequalification of medicines programme. J Public Health Policy 35(2):137–161
Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61(5):455–463
Karalis V, Bialer M, Macheras P (2013) Quantitative assessment of the switchability of generic products. Eur J Pharm Sci 50(3–4):476–483
Gwaza L, Gordon J, Potthast H, Welink J, Leufkens H, Stahl M, et al (2014) Adjusted indirect treatment comparison of the bioavailability of WHO-prequalified first-line generic antituberculosis medicines. Clin Pharmacol Ther 96(5):580–588
Karalis V, Macheras P, Bialer M (2014) Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations. CNS Drugs 28(1):69–77
Julious SA (2004) Sample sizes for clinical trials with normal data. Stat Med 23(12):1921–1986
The European Parliament and the Council of the European Union (2001) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Off J Eur Communities 311:108
The United States Pharmacopeia Convention. Carbamazepine tablets USP (2009).
Boix-Montañes A, Garcia-Arieta A. (2015) Composition specification of teicoplanin based on its estimated relative bioavailability. Drug Dev Ind Pharm 41(2):218–23
Anderson S, Hauck WW (1996) The transitivity of bioequivalence testing: potential for drift. Int J Clin Pharmacol Ther 34(9):369–374
Herranz M, Morales-Alcelay S, Corredera-Hernandez MT, de la Torre-Alvarado JM, Blazquez-Perez A, Suarez-Gea ML, et al (2013) Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison. Eur J Clin Pharmacol 69:1157–1162
Conflict of interest
The authors declare that they have no conflict of interest.
Author contributions
L.G., J.G., and A.G-A wrote the manuscript; L.G., J.G., H.L., J.W., H.P., M.S., and A.G-A designed the research; L.G. and A.G-A performed the research; and L.G. and A.G-A analyzed the data.
Author information
Authors and Affiliations
Corresponding author
Additional information
This manuscript represents the personal opinion of the authors and does not necessarily represent the views or policy of their corresponding Regulatory Agencies.
Rights and permissions
About this article
Cite this article
Gwaza, L., Gordon, J., Potthast, H. et al. Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons. Eur J Clin Pharmacol 71, 1083–1089 (2015). https://doi.org/10.1007/s00228-015-1889-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-015-1889-9